Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.930.02%
QQQ
707.830.03%
BTC/USD
77470.900.1013%
DIA
527.670.02%
GLD
396.500.06%
TLT
81.830.05%

Adaptive Biotechnologies Corp

ADPTNASDAQ
Trade with Public
Trade with Public
$24.34
-0.58-2.33%
At close: Sep 1, 5:00 PM EST
$23.55
-0.79-3.23%
After Hours: 6:19 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Adaptive Biotechnologies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Adaptive Biotechnologies (ADPT).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$20Upside to Avg. PT-13.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Piper SandlerDavid WestenbergPT RaiseOverweight$20→$28
Jul 30, 2026Morgan StanleyTejas SavantPT RaiseEqual-Weight$20→$22
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $22 to $25.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved